GENE Therapy Payment Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act
This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
Referred to the House Committee on Energy and Commerce.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 5882: GENE Therapy Payment Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-5882/
"H.R. 5882: GENE Therapy Payment Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-5882/.
H.R. 5882, 116th Cong. (2026), https://openamerica.io/bill/116-HR-5882/.
[H.R. 5882: GENE Therapy Payment Act](https://openamerica.io/bill/116-HR-5882/)